Dose-response studies of quazepam

Anthony Kales, Martin B. Scharf, Edward O. Bixler, Paula K. Schweitzer, Judith A. Jacoby, Constantin R. Soldatos

Research output: Contribution to journalArticlepeer-review

24 Scopus citations


Quazepam, an investigational benzodiazepine, was evaluated in doses of 7.5, 15, and 30 mg in a 12-night protocol including four nights of drug trial. All three doses were effective in inducing and maintaining sleep, with the highest degree of effectiveness after the first drug night. Carry-over effectiveness, which was seen after withdrawal of all three doses, persisted throughout the withdrawal period after the 30-mg dose. Quazepam's effects during both drug use and withdrawal appeared to be dose related; 15 mg induced a greater reduction in wake time after sleep onset than the 7.5-mg dose, and 30 mg induced even greater differences in both wake time after sleep onset and total wake time. Subjective reports of improved sleep were in general agreement with the objective data at each dose level. Side effects appeared to be dose related in terms of severity. The efficacy and comparatively less severe side effects of the 7.5- and 15-mg doses of quazepam suggest that these doses may be optimal when the drug is considered for the adjunctive treatment of insomnia.

Original languageEnglish (US)
Pages (from-to)194-200
Number of pages7
JournalClinical pharmacology and therapeutics
Issue number2
StatePublished - Aug 1981

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Dose-response studies of quazepam'. Together they form a unique fingerprint.

Cite this